Cargando…
Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 20...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687954/ https://www.ncbi.nlm.nih.gov/pubmed/38031361 http://dx.doi.org/10.1177/15330338231218152 |
_version_ | 1785152080839704576 |
---|---|
author | Lin, Binwei Fan, Jinjia Liu, Fang Wen, Yixue Li, Jie Gao, Feng Zhang, Yu Feng, Gang Du, Xiaobo Chen, Wenzhi |
author_facet | Lin, Binwei Fan, Jinjia Liu, Fang Wen, Yixue Li, Jie Gao, Feng Zhang, Yu Feng, Gang Du, Xiaobo Chen, Wenzhi |
author_sort | Lin, Binwei |
collection | PubMed |
description | Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 2022 were included in this retrospective study. Docetaxel + trastuzumab + pertuzumab or docetaxel + carboplatin + trastuzumab + pertuzumab was selected as the neoadjuvant regimen. The primary endpoint was a complete pathological remission rate. Secondary endpoints were toxicity during neoadjuvant treatment, adjustment of the neoadjuvant therapy scheme, and adjuvant medication. Result: A total of 81 patients were included in this study (38 in the docetaxel + carboplatin + trastuzumab + pertuzumab treatment group and 43 in the docetaxel + trastuzumab + pertuzumab group). The complete pathological remission rates in the docetaxel + carboplatin + trastuzumab + pertuzumab and docetaxel + trastuzumab + pertuzumab groups were 44.7% (95% confidence interval: 30.2%-60.3%) and 51.2% (95% confidence interval: 36.8%-65.4%), respectively. The incidence of grade 3 or higher toxicity in the docetaxel + carboplatin + trastuzumab + pertuzumab group was significantly higher than that in the docetaxel + trastuzumab + pertuzumab group (68.4% vs 39.5%, P = .009). Neutropenia and asthenia were the most common grade 3 or higher toxicities. The incidence of neoadjuvant scheme adjustment was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (26.3% vs 7.0%, P = .039). The proportion of patients who received <6 cycles of neoadjuvant therapy was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (31.6% vs 4.7%, P = .004). Patients in the docetaxel + carboplatin + trastuzumab + pertuzumab group received higher doses of granulocyte-macrophage colony-stimulating factor. Conclusion: In the neoadjuvant treatment of HER2-positive breast cancer, the docetaxel + trastuzumab + pertuzumab regimen might be more tolerated than the docetaxel + carboplatin + trastuzumab + pertuzumab regimen and did not show a lower complete pathological remission rate. However, our findings require further validation through prospective studies. |
format | Online Article Text |
id | pubmed-10687954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-106879542023-11-30 Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer Lin, Binwei Fan, Jinjia Liu, Fang Wen, Yixue Li, Jie Gao, Feng Zhang, Yu Feng, Gang Du, Xiaobo Chen, Wenzhi Technol Cancer Res Treat Navigating Breast Health: From Screening to Survivorship Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 2022 were included in this retrospective study. Docetaxel + trastuzumab + pertuzumab or docetaxel + carboplatin + trastuzumab + pertuzumab was selected as the neoadjuvant regimen. The primary endpoint was a complete pathological remission rate. Secondary endpoints were toxicity during neoadjuvant treatment, adjustment of the neoadjuvant therapy scheme, and adjuvant medication. Result: A total of 81 patients were included in this study (38 in the docetaxel + carboplatin + trastuzumab + pertuzumab treatment group and 43 in the docetaxel + trastuzumab + pertuzumab group). The complete pathological remission rates in the docetaxel + carboplatin + trastuzumab + pertuzumab and docetaxel + trastuzumab + pertuzumab groups were 44.7% (95% confidence interval: 30.2%-60.3%) and 51.2% (95% confidence interval: 36.8%-65.4%), respectively. The incidence of grade 3 or higher toxicity in the docetaxel + carboplatin + trastuzumab + pertuzumab group was significantly higher than that in the docetaxel + trastuzumab + pertuzumab group (68.4% vs 39.5%, P = .009). Neutropenia and asthenia were the most common grade 3 or higher toxicities. The incidence of neoadjuvant scheme adjustment was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (26.3% vs 7.0%, P = .039). The proportion of patients who received <6 cycles of neoadjuvant therapy was significantly higher in the docetaxel + carboplatin + trastuzumab + pertuzumab group than in the docetaxel + trastuzumab + pertuzumab group (31.6% vs 4.7%, P = .004). Patients in the docetaxel + carboplatin + trastuzumab + pertuzumab group received higher doses of granulocyte-macrophage colony-stimulating factor. Conclusion: In the neoadjuvant treatment of HER2-positive breast cancer, the docetaxel + trastuzumab + pertuzumab regimen might be more tolerated than the docetaxel + carboplatin + trastuzumab + pertuzumab regimen and did not show a lower complete pathological remission rate. However, our findings require further validation through prospective studies. SAGE Publications 2023-11-29 /pmc/articles/PMC10687954/ /pubmed/38031361 http://dx.doi.org/10.1177/15330338231218152 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Navigating Breast Health: From Screening to Survivorship Lin, Binwei Fan, Jinjia Liu, Fang Wen, Yixue Li, Jie Gao, Feng Zhang, Yu Feng, Gang Du, Xiaobo Chen, Wenzhi Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer |
title | Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer |
title_full | Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer |
title_fullStr | Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer |
title_full_unstemmed | Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer |
title_short | Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer |
title_sort | efficacy and safety of dual anti-her2 blockade and docetaxel with or without carboplatin as neoadjuvant regimen for treatment of her2-positive breast cancer |
topic | Navigating Breast Health: From Screening to Survivorship |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687954/ https://www.ncbi.nlm.nih.gov/pubmed/38031361 http://dx.doi.org/10.1177/15330338231218152 |
work_keys_str_mv | AT linbinwei efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer AT fanjinjia efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer AT liufang efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer AT wenyixue efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer AT lijie efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer AT gaofeng efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer AT zhangyu efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer AT fenggang efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer AT duxiaobo efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer AT chenwenzhi efficacyandsafetyofdualantiher2blockadeanddocetaxelwithorwithoutcarboplatinasneoadjuvantregimenfortreatmentofher2positivebreastcancer |